Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

Inclusion Criteria: * Willing to be followed for the duration of the study * Willing to use acceptable methods of contraception * Good general health Exclusion Criteria: * Clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the volunteer to understand and cooperate with the study * Hematologic disease * Alcohol or drug abuse within 12 months prior to study entry * History of severe allergic reaction or anaphylaxis * Emergency room visit or hospitalization for severe asthma within 6 months prior to study entry * HIV-1 infected * Hepatitis C virus infected * Hepatitis B surface antigen positive * Known immunodeficiency syndrome * Use of corticosteroids or immunosuppressive drugs within 30 days prior to study entry. Participants who have used topical or nasal corticosteroids are not excluded. * Live vaccine within 4 weeks prior to study entry * Killed vaccine within 2 weeks prior to study entry * Blood products within 6 months prior to study entry * Participation in another investigational vaccine or drug trial within 60 days of starting this study, or while this trial is ongoing * Previously received a licensed or experimental yellow fever or dengue vaccine * Surgical removal of spleen * History of dengue virus infection or other flavivirus infection (e.g., yellow fever virus, St. Louis encephalitis, West Nile virus, Japanese encephalitis virus) * Other condition that, in the opinion of the investigator, would affect the participant's participation in the study * Plan to travel to an area where dengue infection is common * Pregnancy or breastfeeding